Key Highlights
- Revenue was USD 73.43 million against an estimate of USD 76.96 million.
- Loss per share was USD 0.17 against an estimate of a USD 0.11 loss.
- Adjusted EBITDA loss was USD 3.2 million, against USD 6.3 million last quarter.
- Gross Margin improved to 33.3% from 30.5% in the second quarter.
DocGo (NASDAQ:DCGO) reported third quarter 2026 Revenue of USD 73.43 million, against an estimate of USD 76.96 million and USD 70.81 million in the third quarter of 2025. The loss per share was USD 0.17, compared with an estimate of a USD 0.11 loss and a USD 0.28 loss a year earlier.
The loss from operations was USD 17.28 million, compared with USD 41.98 million, and the net loss before income tax was USD 18.21 million, compared with USD 43.17 million. Chief executive officer Lee Bienstock led the earnings call.
Revenue and Segment Results
Mobile Health Services revenues were USD 20.2 million, a decrease of USD 0.5 million, or 2.4%. Transportation Services revenues were USD 53.2 million, an increase of USD 3.1 million, or 6.2%. Management said last year's third quarter included USD 8.4 million of migrant-related revenue, and that excluding that revenue from the comparison, third quarter revenue increased 18%.
Total expenses were USD 90.71 million, compared with USD 112.79 million. General and administrative expenses were USD 28.90 million, compared with USD 30.09 million. Management said adjusted selling, general and administrative expenses were USD 28.7 million, compared with USD 29.7 million in the second quarter and USD 30.8 million in the first quarter.
Guidance and Operating Initiatives
Management reaffirmed its full year 2026 adjusted EBITDA guidance of a loss of USD 17 million to USD 22 million and revised its revenue guidance to approximately USD 300 million from USD 305 million to USD 310 million. The company is winding down its medical transportation Business in Upstate New York, which generates approximately USD 10 million in annual revenue.
Management said its Care in the Home business is anticipated to incur a loss of approximately USD 5 million in 2026, and that the launch of automated outreach through AI voice agents for in-home visits reduced cost per booking by over 50%.
Liquidity and Financing
Unrestricted cash was USD 19.1 million as of September 30, compared with USD 25.2 million at the end of the second quarter. At the beginning of the fourth quarter, the company closed the first Tranche of its Debt Facility with Perceptive Advisors, totaling USD 12.5 million. A further USD 12.5 million is available upon closing of the Hicuity Health transaction, with an additional USD 25 million available, subject to maintaining USD 130 million in Mobile Health revenue.
Management said two major receivables from its discontinued municipal population health business total approximately USD 19 million, comprising a smaller receivable of approximately USD 6.7 million and another of USD 12.6 million.
DocGo Q3 2026 Earnings: Key Takeaways
DocGo reported third quarter 2026 revenue of USD 73.43 million and a loss per share of USD 0.17. Management reported an adjusted EBITDA loss of USD 3.2 million, reaffirmed its adjusted EBITDA guidance, and revised revenue guidance to approximately USD 300 million.






Please wait processing your request...